Republican Rep. Julia Letlow of Louisiana reported a purchase of Abbott Laboratories (ABT) common stock in a Periodic Transaction Report filed with the U.S. House of Representatives. If you have ever searched for a pelosi stock tracker on Twitter or asked whether you can follow trades like these on Reddit, this filing is the kind of paper trail that makes it possible — when it shows up on time.
According to the disclosure, Letlow personally purchased shares of ABT on October 23, 2024. The transaction is valued between $1,001 and $15,000, the standard broad range used in these congressional filings rather than an exact dollar figure. The stock is held through a Merrill Lynch Investment Account, listed on the form as Account #025.
A Filing That Missed the 45-Day Window
The STOCK Act requires members of Congress to disclose new securities transactions within 45 days of the trade. In this case, the report was filed 292 days after the purchase date — well beyond that deadline. We’re noting this delay as a factual part of the record, not as a claim about why it happened. Late filings are logged and tracked by watchdog groups and financial media, but a delay by itself is not evidence of wrongdoing; it simply means the disclosure arrived long after the transaction that triggered it.
People often ask whether congress can do insider trading, and the honest answer is that lawmakers are legally allowed to buy and sell individual stocks. The STOCK Act does not ban these trades — it requires that they be disclosed publicly so voters, journalists, and investors can see them. That transparency requirement is the entire reason a report like this one exists in the first place.
What the Trade Itself Shows
Abbott Laboratories is a large, well-known healthcare and diagnostics company, and a purchase in the $1,001–$15,000 range is a relatively modest position size relative to the total value often seen in these filings. We’re classifying this as a congress buy signal in our tracking system, meaning a sitting member of the House added to a position in a publicly traded company during the disclosed period.
No sale, option, or additional transaction tied to this account is included in the filing beyond what’s listed here. As with all Periodic Transaction Reports, this document reflects only what Rep. Letlow’s office submitted to the House; it does not include commentary on strategy, timing, or rationale. Readers looking to track additional congressional trading activity involving ABT or other members can check back as new disclosures are filed.